Cesca Therapeutics (KOOL) Set to Announce Quarterly Earnings on Tuesday

Cesca Therapeutics (NASDAQ:KOOL) is set to post its quarterly earnings results after the market closes on Tuesday, August 13th. Analysts expect Cesca Therapeutics to post earnings of ($0.60) per share for the quarter.

Cesca Therapeutics (NASDAQ:KOOL) last posted its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.06) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.02. The business had revenue of $2.96 million during the quarter, compared to analyst estimates of $3.10 million. Cesca Therapeutics had a negative return on equity of 51.45% and a negative net margin of 355.50%. On average, analysts expect Cesca Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cesca Therapeutics stock opened at $2.86 on Wednesday. The company has a market cap of $7.00 million, a price-to-earnings ratio of -0.79 and a beta of 1.00. The business has a fifty day simple moving average of $3.07. Cesca Therapeutics has a 12 month low of $2.10 and a 12 month high of $5.25. The company has a current ratio of 1.58, a quick ratio of 0.81 and a debt-to-equity ratio of 0.54.

Separately, ValuEngine raised Cesca Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, July 2nd.

Cesca Therapeutics Company Profile

Cesca Therapeutics Inc develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products.

Featured Article: Why does the United States have a lingering trade deficit?

Earnings History for Cesca Therapeutics (NASDAQ:KOOL)

Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.